A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies
The primary objectives of the study are: - To determine the safety and the maximum tolerated dose (MTD) of IPI-926 - To examine the pharmacokinetic parameters of IPI-926 and its characterized major metabolite(s) - To recommend a dose and schedule of IPI-926 for subsequent studies
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : IPI-926
Phase: Phase 1
Ages Eligible For Study:
1. Pathologically confirmed diagnosis of a solid tumor for which no standard therapy proven to provide clinical benefit is available. 2. ?18 years of age 3. Life expectancy of at least 3 months. 4. ECOG performance status of 0 to 2. 5. Ability to follow the study and all protocol requirements. 6. Voluntarily sign an informed consent form 7. Women of child-bearing potential (WCBP), defined as a sexually mature woman who has not undergone a hysterectomy or tubal ligation of who has not been naturally postmenopausal for at least 24 consecutive months, must have a negative serum or urine pregnancy test prior to treatment. All WCBP, all sexually active male patients, and all partners of patients must agree to use adequate methods of birth control throughout the study. 8. Recovery to </= Grade 1 or baseline of any toxicities due to prior treatments, excluding alopecia.